CLEVIPREX® (clevidipine) has individualized, titratable dosing and administration

Cleviprex vials

Low-volume, non–weight-based dosing1

  • Administered intravenously by a dedicated central or a dedicated peripheral line
  • Single-use parenteral emulsion* that contains 0.005% EDTA to inhibit the rate of growth of microorganisms for up to 12 hours
  • Metabolized by esterases in the blood and extravascular tissues
    • Elimination is unlikely to be affected by hepatic or renal dysfunction

*CLEVIPREX contains approximately 0.2 g of lipid per mL (2.0 kcal).

50 mL and 100 mL CLEVIPREX single-use, ready-to-use vials

50 mL vial lasts

~4–6 hours

100 mL vial lasts

~8–12 hours

Most patients will achieve the desired therapeutic response at approximately 4–6 mg/hr.

Individualized, titratable administration1

Initiate Icon


  • Initiate intravenous CLEVIPREX infusion at 1–2 mg/hr (2–4 mL/hr)
    • This includes patients with abnormal hepatic function and moderate to severe renal impairment
  • Individualize dosage depending on the response of the patient and the BP goal
  • Most patients were treated with maximum doses of 16 mg/hr or less
Cleviprex Dosing Calculator
1 mg/hr
2 mL/hr
2 mg/hr
4 mL/hr
4 mg/hr
8 mL/hr
6 mg/hr
12 mL/hr
32 mg/hr
64 mL/hr

Must enter a whole number.

Please enter a whole number between 1‑32.

Must enter a whole number.

Please enter an even number between 2‑64.

Titrate Icon


  • Dose may be doubled every 90 seconds initially
  • As BP approaches goal:
    • Increase dose by less than double
    • Lengthen time between dose adjustments to every 5–10 minutes
  • An approximately 1–2 mg/hr (2–4 mL/hr) increase will generally produce an additional 2–4 mmHg decrease in SBP
  • Most patients achieve desired therapeutic response at 4–6 mg/hr (8–12 mL/hr)
    • Severe hypertension may require doses up to 32 mg/hr (64 mL/hr), but there is limited experience at this dose rate

Monitor Icon


  • Monitor blood pressure and heart rate continually during infusion, and then until vital signs are stable
  • Patients who receive prolonged CLEVIPREX infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped. These patients may need follow-up adjustments in BP control

Optimizing CLEVIPREX administration1

Before Administration

During Administration

  • Maintain strict aseptic technique
  • Inspect package and bottle for any defects and bottle contents for particulate matter, discoloration, or contaminants; do not use if contamination is suspected
  • Invert vial gently several times before use to ensure uniformity of the emulsion
  • Once stopper is punctured, use within 12 hours and discard any unused portion
  • Because CLEVIPREX is a low-volume infusion, it is crucial to prime the IV tubing and check for dead space
  • Manage lack of response
    • Ensure CLEVIPREX is getting to the patient by checking for dead space
    • Individual patient response may vary
  • Note rapid onset and offset of CLEVIPREX when changing the IV set or vial


Watch the CLEVIPREX dosing and administration video


Dr. Horowitz speaks about CLEVIPREX

Renowned anesthesiologist Dr. Todd Horowitz discusses CLEVIPREX clinical trial results and dosing in a series of informative videos for healthcare professionals.

The CLEVIPREX Dosing and Administration Guide

Use this guide as a quick reference to help with CLEVIPREX dosing and administration.

Transitioning off CLEVIPREX

Learn what to consider when transitioning patients off CLEVIPREX.

Recommended in Stroke Guidelines

CLEVIPREX has been recommended in the AHA/ASA Acute Ischemic Stroke Guidelines since 2018.2